it is normally 12-37 repeats and becomes expanded to there is strong immunostaining for ataxin-3 within the nuclei of neurons ( Figure 2 ). In individual neurons, this 61-84 repeats in affected individuals.
In this paper, we present evidence for aberrant localstaining takes the form of one to three spherical intranuclear structures varying in size from 0.5 to ‫6ف‬ m in ization and probable aggregation of this polyglutamine disease protein in human disease tissue. Our studies of diameter. In some neurons, the inclusion spans more than half the diameter of the nucleus, but the most com-SCA3/MJD brain demonstrate that ataxin-3, normally a predominantly cytoplasmic protein, accumulates in monly observed pattern is a singlet or doublet structure near to, yet clearly distinct from, the hematoxylinubiquitinated nuclear inclusions (NI) that are found selectively in neurons known to be affected by the disease stained nucleolus (Figure 2d ). NI were seen in both ethanol-and formaldehyde-fixed tissue, with short and long process. The results take on an added significance in light of recent findings showing neuronal NI in transgenic postmortem intervals. Staining was not observed with preadsorbed or preimmune serum or in the absence of models of other polyglutamine diseases (Davies et al., 1997; H. Orr and H. Zoghbi, personal communication) primary serum. The inclusions were not autofluorescent, thus distinguishing them from the inclusions seen in the and suggest that, although the various polyglutamine disease proteins normally may be present in different rare disorder, neuronal intranuclear inclusion disease (NIID; Palo et al., 1984; Garen et al., 1986 ; Weidenheim cellular compartments, the nucleus is a primary site of pathogenesis for this class of diseases. In further studies and Dickson, 1995) . NI were seen only in neurons and never in glial cells, in vitro, we present evidence supporting a model of disease in which full-length disease protein is recruited despite the fact that many glial cells stain for ataxin-3 in normal and in diseased brain . into aggregates by a polyglutamine fragment.
NI were found most frequently in neurons of the ventral pons, a primary target region in SCA3/MJD (Sachdev et Results al., 1982; Yuasa et al., 1986; Takiyama et al., 1994) . They were also seen, less frequently, in other regions known Nuclear Inclusions (NI) of Ataxin-3 in Neurons of SCA3/MJD Brain to be affected in disease: substantia nigra, globus pallidus, dorsal medulla, and dentate nucleus. NI were not In an earlier study, we generated antiserum specific for the MJD1 gene product ataxin-3 .
found in regions typically spared in disease, including cerebral cortex, hippocampus, striatum, and the Pur- Figure 1 shows a representative immunoblot with this antiserum, also the principal immune serum used in the kinje cell layer of the cerebellum. Even though it is generally not thought to be a major target in disease, the current study. With this antiserum, we previously demonstrated that both normal and expanded repeat inferior olivary complex contained infrequent NI. To confirm that these structures were specific to the ataxin-3 are expressed widely in diseased brain and throughout the body. In immunohistochemical studies disease state, we quantitated NI in the ventral pons of four SCA3/MJD brains and five control brains (Table 1) . of normal brain, ataxin-3 was localized to neuronal and nonneuronal cells in a predominantly, but not exclu-NI were present in all four SCA3/MJD brains, with one or more NI found in slightly less than half the neurons. sively, cytoplasmic distribution. Staining also extended into neuronal processes and occasionally was observed NI were absent from all five controls. The frequency of NI in several other affected regions was lower but not within the nuclei of neurons in a faint punctate pattern.
In diseased brain, the subcellular distribution of quantitated.
To confirm that the inclusions contain ataxin-3, ataxin-3 differs in at least one important respect: in several brain regions that are known targets of disease, we performed double labeling immunofluorescence in which the polyclonal ataxin-3 antiserum was paired with ataxin-3 throughout the inclusion ( Figure 3 ). As with ataxin-3 immunostaining, ubiquitin immunostaining dema monoclonal antibody (MAb) specific for ataxin-3 (1H9) or with MAb 1C2, the polyglutamine-specific antibody onstrated that NI size varies considerably, in some cases nearly fully occupying the nucleus (Figure 4a ; see also that preferentially recognizes expanded glutamine domains (Trottier et al., 1995b) . In diseased brain, both the lower portion of Figure 3 ). Again, brain regions that are known targets of disease showed intranuclear ubiMAbs labeled the same nuclear structures as did the polyclonal antiserum (Figure 3 ). Serial confocal images quitin staining, whereas unaffected regions did not. In a systematic survey of brain regions, ubiquitin-positaken through an inclusion demonstrated the immunofluorescence signal in all focal planes, indicating that tive spherical bodies were found only in neurons and were nearly always intranuclear; only two clearly cytoataxin-3 is present throughout these structures ( Figure  3 ). Staining of NI with 1C2 further confirms that the plasmic ubiquitin inclusions were seen in two thoroughly examined SCA3/MJD brains. It is important to note, pathologic expanded glutamine domain is present within these inclusions.
however, that ubiquitination in SCA3/MJD brain is not limited to NI. In affected regions, for example, densely immunoreactive deposits were often seen near neurons Ataxin-3 Inclusions Are Ubiquitinated Ubiquitination is a common feature of many neuropatho- (Figure 4c ). We do not know whether these represent the residue of dead or dying neurons or ubiquitin-positive logic structures, such as the Lewy body of Parkinson's disease (Lowe et al., 1993; Galvin et al., 1997) . Its presnonneuronal cells; staining of adjacent thin sections with ataxin-3 antisera indicated that many of these deposits ence in neuropathologic structures is thought to reflect aberrant protein folding or degradation. We therefore contain ataxin-3 (not shown). Diffuse cytoplasmic labeling for ubiquitin was also seen in some neurons of the determined whether NI also contain ubiquitin. In coimmunofluorescence studies, ubiquitin colocalized with substantia nigra and cervical cord. Lastly, many larger ubiquitin-positive structures resembling corpora amylacea were observed in the globus pallidus, pons, and Shown are confocal coimmunofluorescence images of SCA3/MJD pontine neurons (top three rows) and a control pontine neuron (bottom row) labeled with ataxin-3-specific MAb 1H9, polyglutamine-specific MAb 1C2, or anti-ubiquitin (left), together with ataxin-3 polyclonal antiserum (center). Composite images (right) demonstrate colocalization of label in NI in SCA3/MJD neurons; note that 1C2 weakly labels NI, yielding a green instead of a yellow composite image. The punctate cytoplasmic labeling seen in the rhodamine images is largely autofluorescence, is seen in both diseased and control neurons, and roughly defines the nuclear border. All sets of panels are summed images through the entire inclusion, except the anti-ubiquitin panels (third row from the top), which represent a single 0.5 m focal plane through the center of a large inclusion, demonstrating that immunolabel is present deep within the structure.
notable is the absence of staining for neurofilament encoding either full-length ataxin-3 or a carboxy-terminal fragment of the protein consisting of the glutamine proteins, a common component of many ubiquitinated structures, including Lewy bodies and the inclusions of repeat with short flanking sequences. For these studies, the normal and expanded polyglutamine tracts were 27 NIID (Palo et al., 1984; Lowe et al., 1993; Galvin et al., 1997) .
and 78 repeats, respectively. In transfected cells, we observed diffuse cytoplasmic staining for full-length ataxin-3 with a normal or expanded glutamine repeat, Intracellular Aggregates Formed by an Expanded Glutamine Fragment as well as for the truncated protein containing a normal repeat ( Figure 5A ). This result is consistent with our The presence in SCA3/MJD of NI containing ataxin-3 suggested that expanded ataxin-3 aggregates within observation that endogenous ataxin-3 has a predominantly cytoplasmic distribution in several human cell the nucleus. To model this in vitro, we transfected human kidney epithelial 293T cells with expression constructs lines (unpublished data). In contrast, truncated protein with an expanded rethe top of the stack and separating gels ( Figure 6A ). Truncated ataxin-3 with a normal repeat does not form peat did not distribute diffusely within the cytoplasm but rather localized to two distinct subcellular strucsuch complexes, although it may form SDS-resistant dimers. Likewise, full-length protein with a normal or tures: large cytoplasmic (and occasionally nuclear) spherical bodies that resemble vacuoles under phase expanded repeat does not form high molecular weight complexes. However, when coexpressed with an excontrast optics and smaller intranuclear and perinuclear clusters ( Figure 5A ). Greater than 97% of cells transpanded glutamine fragment, full-length ataxin-3 is recruited into insoluble complexes ( Figure 6B ). This was fected with the expanded polyglutamine fragment displayed the larger spherical structures, and many cells determined by showing, in coexpression experiments, that the high molecular weight complexes now become displayed both structures. The larger structures concentrated the lysosomal marker Lysotracker DND-99 and recognizable by antibodies to epitopes present only in the full-length, but not the truncated, protein (results thus may represent acidotropic vesicles, possibly lysosomal in origin (data not shown). The smaller ataxin-3 with the ataxin-3 specific MAb 2B6 are shown; ataxin-3 antiserum gave similar results in separate experiments). inclusions did not appear vesicular, and were most intensely immunolabeled by the polyglutamine-specific Significantly, recruitment of the full-length ataxin-3 into aggregates occurred to an appreciable extent only when MAb 1C2. Confocal imaging confirmed that these smaller clusters were localized to the intranuclear and an expanded glutamine repeat was present in the full protein ( Figure 6B ). These results suggest that a pathoperinuclear space ( Figure 5B ). Although they are smaller than the NI seen in diseased brain, their presence indilogic (expanded) glutamine fragment can serve to initiate or catalyze aggregation of the full-length protein. cates that truncated ataxin-3 can be transported to the nucleus, where it may form microaggregates.
Moreover, the probability that this will occur is dependent upon the length of the glutamine repeat within the Others have shown that expression of an expanded glutamine fragment of ataxin-3 is cytotoxic to COS cells full protein.
Next, we determined whether, along with electro- (Ikeda et al., 1996) . Similarly, we find that truncated ataxin-3 with an expanded glutamine repeat induces phoretic evidence for recruitment, there were corresponding changes in the cellular distribution of fullcell death in 293T cells ( Figure 5C ). The cytotoxicity we observe, however, is less marked than that previously length ataxin-3. To do this, we expressed full-length ataxin-3 together with truncated protein containing an reported, even though the truncated ataxin-3 construct and repeat length used by us is similar. In our hands, expanded repeat, and then performed coimmunofluorescence with antibodies that distinguished the two (Figfor example, many transfected cells survive several days and continue to express the cotransfected marker gene ure 7). In one set of experiments, MAb 2B6 and antihemagglutinin (HA) antibody were used to distinguish lacZ.
full length ataxin-3 from a tagged truncated protein, and in a second set of experiments, the two proteins were Recruitment of Ataxin-3 into Aggregates When expressed in transfected cells, truncated ataxin-3 separately epitope tagged and distinguished with antimyc and anti-HA antibodies. When coexpressed with with an expanded repeat forms insoluble high molecular weight complexes that electrophorese on SDS gels at the truncated protein, full-length ataxin-3 no longer distributed diffusely in the cytoplasm. Instead, it colocawere obtained with expanded ataxin-3. In control experiments, neither of two irrelevant proteins, ␤-galactolized with truncated protein to the same large spherical perinuclear structures that are formed in cells expresssidase and calbindin, colocalized to the subcellular ataxin-3 structures (Figure 7 ; data not shown). The reing just the truncated protein. In contrast to the gel electrophoresis results, which showed that only exsults are consistent with a model in which recruitment is mediated through the glutamine domain of the fullpanded repeat ataxin-3 tends to be recruited into insoluble complexes, the coimmunofluorescence studies length protein and occurs even with a glutamine repeat of normal length. demonstrate that both normal and expanded repeat ataxin-3 are recruited to the spherical structures by a Together, the immunofluorescence and gel electrophoresis studies demonstrate that a coexpressed excoexpressed expanded glutamine fragment. Quantitation of colocalization showed that normal ataxin-3 espanded glutamine fragment markedly alters the intracellular behavior of full-length ataxin-3. In at least one sentially always colocalized with HA-Q78 to intracellular spherical structures (in one experiment, 97 out of 97 important respect, the changes induced by the glutamine fragment differ for normal and expanded ataxin-3. cells in randomly selected fields), and similar results HA-Q78 forms insoluble complexes that migrate in the stack and at the top of the separating gel (arrowhead), while the normal glutamine repeat HA-Q27 forms little if any insoluble complex. Arrows indicate probable monomeric forms of Q27 and Q78. Both also generate higher molecular weight bands that may be SDS-resistant dimers. (B) Full-length expanded ataxin-3 is recruited into insoluble complexes by coexpressed HA-Q78. Lysates from transfected cells were run in parallel on separate gels and probed with: (left) 2B6, which recognizes full-length ataxin-3 but not HA-Q27 or HA-Q78; and (right) anti-HA antibody, which recognizes HA-Q27, HA-Q78, and HA-ataxin78, but not untagged ataxin27. Whereas expanded repeat ataxin-3 is recruited into insoluble complexes (left panel, far right lane), normal repeat ataxin-3 is not (adjacent lane). Note that endogenous ataxin-3 in 293T cells is recognized by MAb 2B6. Results are representative of three experiments.
Whereas both normal and expanded ataxin-3 are reproduct, ataxin-1 (H. Orr and H. Zoghbi, personal communucation). Moreover, in transfected cells, expanded cruited by an expanded glutamine fragment into subcelataxin-1 forms large intranuclear structures (H. Orr and lular structures, only expanded ataxin-3 is recruited into H. Zoghbi, personal communication) . In an HD transinsoluble aggregates. The simplest interpretation is that genic mouse, neuronal NI are formed by a truncated the intermolecular bonds formed between two gluhuntingtin protein containing an expanded repeat (Datamine domains differ significantly, depending upon vies et al. , 1997) . Because the transgene in this mouse whether both domains are expanded versus only one model is only a single exon of the HD gene encoding of the two. a small amino-terminal polyglutamine fragment of the protein (Mangiarini et al., 1996) , some might argue that Discussion it does not precisely mirror the human disease. However, similar intranuclear inclusions have already been noted While the genetic basis of the CAG/polyglutamine repeat in an earlier ultrastructural analysis of HD brain (Roizin diseases is clear, the molecular mechanism of neuronal et al. , 1979) . The presence of NI in three separate CAG/ degeneration remains uncertain. Our results from SCA3/ polyglutamine diseases or models of disease indicates MJD tissue argue strongly for a protein-mediated effect that the disease process may be centered in the nucleus. as the basis of disease. In particular, the presence of
The distribution of NI in SCA3/MJD brain corresponds ubiquitinated NI containing ataxin-3 suggests that agto regions that are known to be affected in disease. gregation of the disease protein occurs within neurons.
Despite this clear and direct correlation, we cannot asAlthough ataxin-3 is normally expressed widely in the sume a causal link between the presence of NI and CNS, there is a direct correlation between brain regions neurodegeneration. Still, there are several plausible that display NI and regions that are known targets in ways NI might perturb neuronal function. It is increasdisease, implying that neuronal NI are an integral part ingly clear that nuclear events are exquisitely regulated of the disease process. Together with recent evidence in a spatial and temporal manner. On mechanical showing similar NI in transgenic models of other CAG/ grounds alone, NI could disrupt spatially coordinated polyglutamine repeat diseases, our results suggest that nuclear processes such as transcription and splicing. the nucleus is a primary site of pathogenesis in this Alternatively, NI might sequester important nuclear facclass of neurodegenerative disorders.
tors, thereby altering gene expression. Because of its own polymorphic glutamine repeat (Imbert et al., 1994) , The Nucleus as a Primary Site of Pathogenesis the TATA-binding protein is one potential candidate for Are NI pathologic features shared by all CAG/polyglusequestration along with a polyglutamine disease protamine diseases? Recent studies of two other diseases tein. A third possibility is that the formation of NI reflects, suggest that this may be the case. In the SCA1 or causes, a breakdown in normal proteolytic processes transgenic mouse (Burright et al., 1995) , degenerating within the nucleus. Proteosomes are abundant in the nuclei of neurons (Mengual et al., 1996) , suggesting that Purkinje cells develop NI that contain the SCA1 gene intranuclear proteolysis is one way for the cell to prein an inaccessible, insoluble form within NI. In SCA3/ MJD, NI must contain regions of the ataxin-3 protein cisely regulate the relative abundance of nuclear factors. Even subtle changes in normal nuclear proteolysis might outside of the glutamine domain, because NI are labeled by 1H9, an ataxin-3 specific MAb that fails to recognize perturb this homeostasis. Further molecular analysis of NI in SCA3/MJD should help determine whether nuclear the carboxy-terminal glutamine fragment of the protein.
Whether NI include the full protein, however, is unknown. functions are disrupted.
NI apparently form in CAG/polyglutamine repeat dis-NI have been described in relatively few neurologic disorders, including viral diseases, oculopharyngeal eases regardless of the normal cellular distribution of the protein. While ataxin-1 is normally found in the nucleus, muscular dystrophy (Blumen et al., 1996) , and NIID (Palo et al., 1984; Garen et al., 1986 ; Weidenheim and Dickson, both huntingtin and ataxin-3 are predominantly cytoplasmic proteins (DiFiglia et al., 1995; Gutekunst et al., 1995) . Clinically, the last of these most closely resembles CAG/polyglutamine diseases. Some patients with NIID 1995; Servadio et al., 1995; Sharp et al., 1995; Trottier et al., 1995a; Paulson et al., 1997) . In fact, further immudevelop progressive ataxia with extrapyramidal features, also one of the most common clinical presentanocytochemical studies of ataxin-3 in cell lines indicate that the protein's subcellular distribution is actually tions in several CAG/polyglutamine diseases. The two can, however, be distinguished on several grounds. complicated and includes nuclear expression in a small percentage of cells (M. Perez and H. Paulson, unpub- NIID, which is a rare and probably heterogeneous disorder, does not show the dominant inheritance pattern of lished data); and according to one report, huntingtin may localize to the nucleus as well as the cytoplasm most CAG/polyglutamine diseases. Moreover, the inclusions in NIID, unlike those in SCA3/MJD, are autofluores- (DeRooij et al., 1996) . These facts raise an important question: do NI derive from a normal nuclear pool of the cent, may contain neurofilament antigen, and are found throughout the brain. Still, some cases of adult onset disease protein or from the larger cytoplasmic pool? Equally important, does the disease protein within NI NIID could represent sporadic forms of CAG/polyglutamine repeat diseases, a testable hypothesis now that represent the full protein, a polyglutamine fragment, or some combination? In CAG/polyglutamine diseases, the antibodies are available for expanded polyglutamine tracts and many of the disease proteins. formation of polyglutamine-containing proteolytic fragments of the disease protein has been proposed as the mechanism of neurodegeneration (Goldberg et al., 1996;  Ubiquitination in Disease NI of ataxin-3 are disease-specific structures, and as Ikeda et al., 1996) . Although we have been unable to detect proteolytic fragments of ataxin-3 in diseased such constitute a pathologic hallmark of SCA3/MJD. The presence of ubiquitin, as well, in NI indicates that brain , it is possible that they exist they likely represent pathologic aggregates of the disexpanded ataxin-3, and (3) recruit expanded ataxin-3 into insoluble complexes. The last of these three deease protein. Although ubiquitination is a normal part of the cell's proteolytic pathways, its occurrence in pends upon the presence of an expanded repeat in the full protein, implying that recruitment into aggregates pathologic structures is thought to reflect misfolding, aggregation, or aberrant degradation of proteins (Lowe occurs via direct interactions between glutamine domains. Subcellular redistribution of full-length ataxin-3 et Galvin et al., 1997) . Except for a single report showing ubiquitination of huntingtin (Kalchman et al., also may be mediated directly through the glutamine domain, since control proteins lacking polyglutamine do 1996), very little is known about the normal degradation of polyglutamine disease proteins. It will be important not undergo cellular redistribution. We conclude that, in vitro, a pathologic polyglutamine fragment can serve to determine whether ataxin-3 normally is degraded via the ubiquitin-proteosome pathway, and whether this as the seed or catalyst for glutamine-mediated aggregation of the full protein. If similar events take place in pathway is disrupted or altered by an expanded glutamine domain. Currently, it is unknown whether the ubivivo, the CAG/polyglutamine repeat diseases may prove analogous to prion diseases, in which protease-resisquitin within NI is covalently attached to ataxin-3 or to other proteins. Further biochemical analysis of ataxin-3 tant forms of prion can induce misfolding and/or aggregation of the normal prion protein (Come et al., 1993; inclusions should help determine whether the disease protein is directly ubiquitinated and whether compoDeArmond and Prusiner, 1995). An intriguing feature of CAG/polyglutamine diseases nents of the proteosome are sequestered within these structures.
is their cell specificity. Each disease causes degeneration only of neurons, and only in selective brain regions, In SCA3/MJD, both the ubiquitin-positive NI and the presumably extracellular ubiquitin deposits are found despite widespread expression of the disease protein.
Although higher expression levels of the disease protein only in affected brain regions, indicating that ubiquitination is either an integral part of, or at the very least a in susceptible populations of neurons may contribute to this cell specificity, as has been reported in HD (Kosindirect consequence of, the disease process. Our results, together with results showing ubiquitin in the NI of HD ski et al., 1997), this can only be part of the answer. Our results suggest that a pathogenic element in SCA3/MJD transgenic mice (Davies et al., 1997) , imply that ubiquitination may be a general feature of CAG/polyglutamine is the intranuclear aggregation of ataxin-3 in susceptible neurons. Based on our in vivo and in vitro studies, we diseases. It will be important to determine whether ubiquitination is seen in pathologic material from other CAG/ propose that cell specificity is in part determined by differing propensities for ataxin-3 aggregation in differpolyglutamine diseases. Unfortunately, human disease tissue provides us with only a single glimpse in time of ent neuronal populations. In a subset of neurons, aggregation would be promoted by any of the following: (1) the last stage in the disease process. Based on our current studies of disease tissue, for example, we canincreased production of a proteolytic glutamine fragment; (2) increased misfolding of the nascent polypepnot know whether the ubiquitin deposits seen in the parenchyma of SCA3/MJD represent the end result of tide or unfolding of the mature protein; (3) increased targeting of ataxin-3, or a proteolytic fragment, to the neurodegeneration. Careful and systematic analysis of transgenic models of disease will help determine the nucleus; and (4) increased total expression of ataxin-3. The last of these not only would raise local concentratemporal relation of ubiquitination to cell death.
If ubiquitinated NI contain aggregated ataxin-3, why tions of the disease protein (perhaps thereby promoting self-aggregation), but in the process might lead to an don't we observe high molecular weight complexes of ataxin-3 on electrophoretic analysis of disease tissue? increase in pathways (1) through (3) as well. A widely held view is that cell specificity in CAG/polyWe suspect that NI from diseased brain remain insoluble with standard techniques of homogenization, lysis, and glutamine repeat diseases arises, in part, from differences among neurons in the set of proteins that normally sample preparation, and thus are too large to enter the stack of an SDS-polyacrylamide gel. If we succeed in interact with the disease protein. This view and our proposed aggregation model are not mutually exclusive. developing denaturation procedures that can dissociate the insoluble complexes formed in vitro, the same denaOn the contrary, normal interacting proteins might be expected to influence the disease protein's subcellular turation procedures will be applied to homogenates from disease brain. It is possible, however, that the distribution, rate of degradation, probability of misfoldaggregates formed in vitro and in vivo are covalently ing, and, most important, the degree to which its glutalinked by transglutaminase-mediated crosslinking (Green, mine domain is exposed or sequestered. Any or all of 1993; Kahlem et al., 1996) , in which case dissociation these events could, in turn, influence the rate of aggremay be impossible.
gation.
Aggregation and Its Relationship to Cell Specificity Experimental Procedures
Because of our in vivo studies showing NI of ataxin-3, we sought to develop an in vitro model of polyglutamine- plexes, (2) cause a cellular redistribution of normal or
Pathologic Tissue

Immunohistochemistry and Immunofluorescence Expression Constructs and Transfection
For most transfections, we used the expression vector pCDNA3 The antibodies and dilutions used in this study are shown in Table  containing either full-length or truncated ataxin-3. Constructs en-2. Ataxin-3 polyclonal antiserum has been described (Paulson et coding full-length ataxin-3 with 27 or 78 CAG repeats, pCDNA3-al., 1997) . MAbs 1H9 and 2B6 specifically bind ataxin-3 at regions MJD27 and pCDNA-HAMJD78, were previously described (Paulson amino-terminal to the glutamine tract and will be described in detail et al., 1997); the latter has an HA epitope at the amino terminus in a separate publication (Trottier et al., unpublished data) . Epitope of the protein. Truncated ataxin-3 constructs were generated by tag antibodies used in this study were the anti-hemagglutinin (HA) digesting ataxin-3 cDNA at the Xmn1 site, 39 bp upstream of the antibodies 12CA5 (Boehringer Mannheim) and Y11 (generously pro-CAG repeat, and placing the resultant carboxy-terminal ataxin-3 vided by D. Merry, Philadelphia) and the anti-myc antibody 9E10 fragment into the Sma1 site of the HA-tagging vector pJ3H (ATCC). (Calbiochem).
The resulting truncated ataxin-3 protein consists of an amino-termiFor immunohistochemistry of brain sections, 6 m sections of nal HA epitope, 12 amino acids of ataxin-3 upstream of the glutamine paraffin-embedded tissue were processed and stained using the repeat, the glutamine repeat (27 or 78 repeats), and the 43 amino peroxidase-DAB technique as previously described (Paulson et al., acids comprising the carboxy-terminus of the protein. This HA-1997). Sections were typically counterstained with hematoxylin. In tagged construct was then subcloned into pCDNA3 for transfection control experiments, the ataxin-3 polyclonal antiserum, anti-ubiquistudies (pCDNA-HAQ27 and pCDNA-HAQ78). Myc-tagged fulltin antiserum, and MAbs 1H9 and 1C2 were screened against seclength ataxin-3 with 78 repeats was generated by subcloning tions of normal pons to ensure that the recognized NI were specific ataxin-3 cDNA from pCDNA-HAMJD78 into the BamH1 site of pJ3M for disease tissue. All four antibodies specifically stained NI both (ATCC), thus replacing the HA epitope with a myc epitope at the by immunofluorescence and by immunohistochemistry. All other amino terminus. antibodies shown in Table 2 were screened against appropriate Subconfluent 293T cells were transfected using calcium phoscontrol brain sections, to verify that the specific antigen was dephate precipitation (Sambrook et al., 1989) . Twenty-four hours after tected at the concentration used.
transfection, cells were plated onto cover slips; 12 hr later, they For coimmmunofluorescence studies of brain tissue, sections were processed for immunofluorescence. Cells were fixed with 4% were labeled with primary antisera, followed by fluorescein isothioparaformaldehyde, permeabilized with 0.05% Triton X-100, and incyanate (FITC) goat anti-rabbit and rhodamine-goat anti-mouse cubated in a blocking solution (2% normal goat serum in PBS with sera, and viewed under standard epifluorescence with an XL-70 0.05% Triton X-100) prior to incubations with antibody. Minolta microscope or with a Leika LSBM laser confocal system
In some experiments, transfected cells were labeled with the orcoupled to a Leitz microscope. In confocal studies, we verified that ganelle-specific dyes Lysotracker red DND-99 (50 nM) and Mitono signal was obtained through the rhodamine channel after excitatracker green FM (200 nM; Molecular Probes) for 60 min prior to tion for FITC, thus ensuring that signal crossover did not occur.
fixation. In these experiments, fixed cells were extracted with ice FITC and rhodamine channels were collected simultaneously, and cold acetone, as recommended by the manufacturer, prior to subsethe digitized images were pseudocolored and recombined using quent immunofluorescence. Adobe Photoshop. For standard immunofluorescence, photographic slides were taken, scanned into digitized images, and proCell Viability cessed with Adobe Photoshop.
In three similar experiments, 35 mm plates of cells were cotransMAb 1C2 recognizes expanded polyglutamine in ataxin-3 and fected with 2 g total plasmid DNA in a 1:4 ratio of RSV-␤Gal to one other polyglutamine disease proteins (Trottier et al., 1995b) but also of the following: pCDNA-MJD78, pCDNA-MJD27, pCDNA-HAQ27, recognizes the glutamine repeat of TATA-binding protein, the propCDNA-HAQ78, or pCDNA3 control plasmid. Viability was assessed tein against which it was initially raised (Lescure et al., 1994) . Howby changes in the morphology of ␤-galactosidase-positive cells. At ever, at very low concentrations of the antiserum, 1C2 specifically 48 and 72 hr after transfection, cells were washed in PBS, fixed in 4% binds to expanded glutamine tracts (I. An and E. Hirsch, personal paraformaldehyde and stained with X-Gal. Blue cells were scored as communication). Therefore, in some immunohistochemistry experiapoptotic or healthy (i.e., nonapoptotic), based on morphological ments of brain tissue, and in all immunofluorescence studies of criteria: small, round blebbing cells were scored as apoptotic and transfected cells, a 1:15,000 dilution of 1C2 was used. Immunohistoall other cells as healthy. For each sample, ten random fields were scored in a blinded manner. Cells transfected with HA-Q78 consischemical staining of NI was still present (albiet weaker) even at tently showed an approximately threefold increase in apoptotic apthis lower concentration, confirming that the pathological expanded pearing cells when compared to all other transfected ataxin-3 conglutamine epitope of ataxin-3 exists within NI. For coimmunofluoresstructs (see Figure 5C ). cence experiments of human tissue, a 1C2 dilution of 1:400 was used.
Quantitation of In Vitro Complexes
In cotransfection experiments, ten randomly selected fields of immunofluorescently labeled cells were viewed under FITC filter and Quantitation of NI scored for the total number of transfected cells expressing HA-Q78 Four SCA3/MJD cases were chosen for analysis, based on the availor HA-Q27 and then for the number of positive cells in which staining ability of equivalent sections through ventral mid-pons. Thin paraffin was punctate (close to 100% for HA-Q78 and 0% for HA-Q27). The sections of ventral pons from four SCA3/MJD individuals (three same fields were then viewed with the rhodamine filter, allowing us separate families) and five controls were labeled immunohistochemto determine the percent of ataxin27-or ataxin78-expressing cells ically with affinity-purified ataxin-3 antiserum and scored for NI by (stained with anti-myc or 2B6) that showed precise colocalization an observer educated in the appearance of inclusions but blinded to spherical structures. Quantitation was performed in a similar manto the origin of the sections. In randomly selected sweeps at 400ϫ, ner for cells transfected singly with ataxin27, ataxin78, HA-Q27, and all pontine neurons in which the nucleus clearly was seen in cross HA-Q78, and for control cotransfections with HA-Q78 and calbindin section were scored for the presence or absence of immunohistoor ␤-galactosidase. On average, ‫001ف‬ cells were counted per experchemically stained intranuclear spherical bodies. (To be seen and imental sample. scored as a distinct structure, the diameter of an inclusion must be ‫5.0ف‬ m or greater.) Neurons (110-150) were scored in each brain, Gel Electrophoresis and Western Blot Analysis and the percentage of neurons containing inclusions was deterTransfected cells were solubilized and prepared for SDS-polyacrylmined for each sample. A mean percent value was then calculated, amide gel electrophoresis as described . Equal shown in Table 1. volumes of equivalent lysates were electrophoresed on discontinuIn one SCA3/MJD brain (the case described by Paulson et al., ous 10% polyacrylamide gels, and both the separating and stacking 1997), we quantitated inclusions from adjacent regions of ventral portions of the gel were transblotted to polyvinylidene difluoride pons that had been fixed separately with 70% ethanol/saline or 4% (PVDF) membrane (DuPont, New England Nuclear). Blots were incuparaformaldehyde. Essentially identical results were obtained for bated with affinity-purified ataxin-3 antiserum (1:1000), MAb 2B6 both fixatives, confirming that the number of NI is independent of (1:1000) or anti-HA MAb 12CA5 (1:3000) in 5% nonfat milk/PBS, followed by horseradish peroxidase-conjugated goat anti-rabbit the method of fixation.
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